ADGM Research | Milton Maxwell

ADGM

Adagio Medical Holdings, Inc.

1.1800

+0.3487+41.9%

Dec 16, 4:00:01 PM EST

Upcoming Earnings

Report date

≈ -/-

Earnings Call Transcripts

This Quarter (Q4 '25)

No earnings call transcript available yet

Last Quarter (Q3 '25)

No earnings call transcript available

Key Stats

Market Cap

24.99M

P/E (TTM)

Basic EPS (TTM)

-2.69

Dividend Yield

Recent Filings

8-K

12/16/25Dec 16, 2025

8-K

12/11/25Dec 11, 2025

8-K

11/12/25Nov 12, 2025

10-Q

11/12/25Nov 12, 2025

8-K

Adagio closes $19M financing

10/20/25Oct 20, 2025

Adagio Medical Holdings closed its private placement on October 20, 2025, raising $19 million upfront from existing and new institutional investors. The funds will support FDA submission for the vCLAS ULTC System based on the completed FULCRUM-VT study, advance next-generation catheter development, and extend cash runway into key milestones. This bolsters execution amid positive clinical feedback from over 350 patients treated. Yet risks persist in regulatory approvals.

About

Adagio Medical Holdings, Inc., a developmental stage medical device company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias. It offers treatment for cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. The company's product portfolio includes iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and accessories; vCLAS ventricular ULTC catheter; and Cryopulse atrial pulsed-field cryoablation catheter and accessories. Adagio Medical Holdings, Inc. was founded in 2011 and is headquartered in Laguna Hills, California.

CEO

Mr. Todd Usen

IPO

8/1/2024

Website

https://adagiomedical.com

Employees

Sector

Healthcare

Industry

Medical Devices